科TRP通道TRPV6的分子药理学
Arthur Neuberger1, Alexander I Sobolevsky1
1Department of Biochemistry and Molecular Biophysics, Columbia University, New York, NY, USA.
Channels (Austin, Tex.)
|October 15, 2023
概括
针对关键通道TRPV6 (过时受体潜在化物6) 的抑制剂对于治疗癌症等疾病至关重要. 最近的结构药理学揭示了通过各种化合物抑制这种子通道的分子机制.
科学领域:
- 分子药理学分子药理学
- 通道生物学 通道生物学
- 在Oncochannel的研究道上.
背景情况:
- 暂时受体潜在化物6 (TRPV6) 是肠道中主要的吸收道.
- TRPV6失调会破坏的平衡,导致疾病,特别是各种癌症.
- 对于有效的TRPV6抑制剂有很大的需求.
研究的目的:
- 审查TRPV6抑制剂结构药理方面的最新进展.
- 阐明TRPV6抑制背后的分子机制.
- 提供各种小分子抑制剂的概述.
主要方法:
- 审查最近的结构药理学研究.
- 对抑制的分子机制的分析.
- 小分子抑制剂的分类 (合成,天然,潜在,已批准的药物).
主要成果:
- 结构药理学的进步揭示了小分子如何抑制TRPV6.
- 包括植物衍生和合成分子在内的各种化合物显示出抑制潜力.
- 了解这些机制为开发新型治疗剂铺平了道路.
结论:
- 结构性见解是理解TRPV6抑制的关键.
- 一系列的小分子可以准TRPV6,提供治疗可能性.
- 对这些抑制剂的进一步研究可能会导致对TRPV6相关疾病的新疗法.
相关概念视频
Non-gated Ion Channels
6.8K
Ion channels are specialized proteins on the plasma membrane that allow charged ions to pass down their electrochemical gradient. Their main function is to maintain the membrane potential which is critical for cell viability. These channels are either gated or non-gated and can transport more than a thousand ions within milliseconds for the cellular event to occur.
Compared to the gated ion channels, the non-gated channels, also known as leakage or passive channels, have no gating mechanism....
Compared to the gated ion channels, the non-gated channels, also known as leakage or passive channels, have no gating mechanism....
6.8K
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
Mechanically-gated Ion Channels
6.4K
Mechanically-gated ion channels are proteins found in eukaryotic and prokaryotic cell membranes that open in response to mechanical stress. Tension, compression, swelling, and shear stress can alter the conformation of the protein, opening a transmembrane channel that allows the passage of ions for signal transmission. In eukaryotes, mechanically-gated channels are distributed in several regions like the neurons, lungs, skin, bladder, and heart, where they play critical roles in numerous...
6.4K
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
Receptor Tyrosine Kinases
13.1K
Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
13.1K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K


